Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Endosc. Mar 16, 2023; 15(3): 153-162
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.153
Table 1 Baseline data of both groups
Characteristic
PPI group (n = 101)
PPI + APG group (n = 95)
P value
Age (yr)51.55 ± 12.2353.57 ± 11.900.245
Female/Male26/7531/640.289
MELD score10.07 ± 3.329.61 ± 3.240.329
Prothrombin activity (%)68.53 ± 15.4865.63 ± 12.900.157
Fibrinogen (g/dL)2.30 ± 0.762.09 ± 0.800.064
Platelet (109/L)102.21 ± 83.68111.16 ± 100.570.498
Albumin (g/dL)3.52 ± 0.473.48 ± 0.580.622
Hemoglobin (g/dL)9.73 ± 2.159.55 ± 1.880.524
Patients treated with beta blockers89860.586
Table 2 Comparison of varicose veins and dose of histoacryl between two groups, n (%)
Characteristic
PPI group (n = 101)
PPI + APG group (n = 95)
P value
GOV110 (9.90)12 (12.63)0.545
GOV250 (49.50)41 (43.16)0.373
GOV334 (33.66)38 (40.00)0.358
IGV17 (6.93)4 (4.21)0.408
Combine with EV need treatment68 (67.33)69 (72.63)0.418
Amount of histoacryl (mL)2.22 ± 0.802.21 ± 0.760.875
Table 3 Main outcomes of both groups, n (%)
Characteristic
PPI group (n = 101)
PPI + APG group (n = 95)
P value
Early rebleeding13 (12.87)3 (3.16)0.013
Source of rebleeding
Glue extrusion ulcer12 (11.88)2 (2.11)0.008
Gastric varice1 (0.99)1 (1.05)> 0.999
Transfusion after rebleeding
Glue extrusion ulcer9 (8.91)1 (1.05)0.030
Gastric varices1 (0.99)1 (1.05)> 0.999
Re-hospitalization10 (9.90)2 (2.11)0.023
6-wk mortality00> 0.999
Table 4 Other adverse events in the two groups, n (%)
Characteristic
PPI group (n = 101)
PPI + APG group (n = 95)
P value
Total complications14 (13.86)12 (12.63)0.800
Abdominal pain12 (11.88)3 (3.16)0.022
Constipation2 (1.98)9 (9.47)0.023
Spontaneous peritonitis00> 0.999
Ectopic embolism00> 0.999
Hepatic encephalopathy00> 0.999